RecruitingNCT04366518
Rivastigmine or scopolamine for hallucinations in psychosis
About this title
Read the official source — NCT04366518Medication studyAges 18–65United StatesSchizophrenia
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- New HavenSee all locations and recruitment
- Study phase
- Early phase 1An early first-in-human or very early safety study, usually focused on how a treatment behaves in the body.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: July 15, 2021
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 35
- Sponsor
- Yale University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Early Phase 1An early first-in-human or very early safety study, usually focused on how a treatment behaves in the body.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT04366518
- Official title
Show the full official title
Toward a Computationally-Informed, Personalized Treatment for Hallucinations
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
New Haven
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Yale University, a university.
Does this study involve medication?
Yes. The study involves medication, including Rivastigmine Transdermal System, Scopolamine and Placebo Patch.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as recruiting.
